Concepedia

Julie A. Stone

JA

60

Publications

4.5K

Citations

38

H-Index

1998

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

Covance (United States)

Vanderbilt University

Julie A. Stone is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

1998–2023

60

Publications

60

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 407 citations

, , +20

Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men

Julie A. Stone, Sherry D. Holland, Peter Wickersham et al. · Antimicrobial Agents and Chemotherapy · 2002 · 246 citations · Full text

Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents

Thomas J. Walsh, Peter C. Adamson, Nita L. Seibel et al. · Antimicrobial Agents and Chemotherapy · 2005 · 238 citations · Full text

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

David C. Turner, Anna Kondic, Keaven M. Anderson et al. · Clinical Cancer Research · 2018 · 205 citations

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease

Jack D. Scott, Sarah W. Li, Andrew P. J. Brunskill et al. · Journal of Medicinal Chemistry · 2016 · 161 citations · Full text

, , +19

Rows per page

1–5 of 60